Role of IL-2 in cancer immunotherapy

References

• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193:1007-8; PMID:181845; http://dx.doi.org/10.1126/science.181845
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26:453-79; PMID:18062768; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090357
   PubMed Web of Science ®Google Scholar
• Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009; 27:29-60; PMID:18817510; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090616
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25; PMID:23352221; http://dx.doi.org/10.1016/j.immuni.2013.01.004
   PubMed Web of Science ®Google Scholar
• Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol 2014; 10:207-17; PMID:24410537; http://dx.doi.org/10.1586/1744666X.2014.875856
   PubMed Web of Science ®Google Scholar
• Paliard X, de Waal Malefijt R, Yssel H, Blanchard D, Chretien I, Abrams J, de Vries J, Spits H. Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. J Immunol 1988; 141:849-55; PMID:2969394; http://dx.doi.org/10.0022-l767/88/1413-0849$02.00
   PubMed Web of Science ®Google Scholar
• Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001; 1:200-8; PMID:11905829; http://dx.doi.org/10.1038/35105066
   PubMed Web of Science ®Google Scholar
• Yui MA, Sharp LL, Havran WL, Rothenberg EV. Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation. J Immunol 2004; 172:4691-9; PMID:15067044; http://dx.doi.org/10.4049/jimmunol.172.8.4691
   PubMed Web of Science ®Google Scholar
• Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10:225-35; PMID:20336151; http://dx.doi.org/10.1038/nri2735
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21:713-58; PMID:12500979; http://dx.doi.org/10.1146/annurev.immunol.21.120601.140942
   PubMed Web of Science ®Google Scholar
• Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140:845-58; PMID:20303875; http://dx.doi.org/10.1016/j.cell.2010.02.021
   PubMed Web of Science ®Google Scholar
• Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011; 241:260-8; PMID:21488902; http://dx.doi.org/10.1111/j.1600-065X.2011.01018.x
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Kronke M, Peffer NJ, Depper JM, Greene WC. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci U S A 1985; 82:6281-5; PMID:3929255; http://dx.doi.org/10.1073/pnas.82.18.6281
   PubMed Web of Science ®Google Scholar
• Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. Immunology 2006; 117:548-57; PMID:16556269; http://dx.doi.org/10.1111/j.1365-2567.2006.02331.x
   PubMed Web of Science ®Google Scholar
• Kronin V, Vremec D, Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol 1998; 10:237-40; PMID:9533452; http://dx.doi.org/10.1093/intimm/10.2.237
   PubMed Web of Science ®Google Scholar
• Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906-11; PMID:20547866; http://dx.doi.org/10.1073/pnas.1002569107
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j.immuni.2009.04.010
   PubMed Web of Science ®Google Scholar
• Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014; 25:377-90; PMID:25200249; http://dx.doi.org/10.1016/j.cytogfr.2014.07.018
   PubMed Web of Science ®Google Scholar
• Cosman D. The hematopoietin receptor superfamily. Cytokine 1993; 5:95-106; PMID:8392875; http://dx.doi.org/10.1016/1043-4666(93)90047-9
   PubMed Web of Science ®Google Scholar
• Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17:349-66; PMID:16911870; http://dx.doi.org/10.1016/j.cytogfr.2006.07.003
   PubMed Web of Science ®Google Scholar
• Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81; PMID:9755337; http://dx.doi.org/10.1016/S0065-2776(08)60386-7
   PubMed Web of Science ®Google Scholar
• Bani L, David D, Moreau JL, Cayota A, Nakarai T, Ritz J, Theze J. Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. Int Immunol 1997; 9:573-80; PMID:9138018; http://dx.doi.org/10.1093/intimm/9.4.573
   PubMed Web of Science ®Google Scholar
• Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science. 2005; 308:1477-80; PMID:15933202; http://dx.doi.org/10.1126/science.1109745
   PubMed Web of Science ®Google Scholar
• Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11:245-68; PMID:8476561; http://dx.doi.org/10.1146/annurev.iy.11.040193.001333
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240:1169-76; PMID:3131876; http://dx.doi.org/10.1126/science.3131876
   PubMed Web of Science ®Google Scholar
• Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998; 16:205-26; PMID:9505189; http://dx.doi.org/10.3109/08830189809042995
   PubMedGoogle Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92; PMID:3903508; http://dx.doi.org/10.1056/NEJM198512053132327
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11:661-70; PMID:8478661; http://dx.doi.org/10.1146/annurev.iy.11.040193.001333
   PubMed Web of Science ®Google Scholar
• Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, Viola M, Sosman JA. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol 2002; 13:606-13; PMID:12056712; http://dx.doi.org/10.1093/annonc/mdf105
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3:157-62; PMID:9161781
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41; PMID:15625368; http://dx.doi.org/10.1200/JCO.2005.03.206
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-8; PMID:9562581; http://dx.doi.org/10.1056/NEJM199804303381805
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-32; PMID:12915604; http://dx.doi.org/10.1200/JCO.2003.02.122
   PubMed Web of Science ®Google Scholar
• Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 1982; 42:913-8; PMID:7059990; http://dx.doi.org/10.0008-5472/82/0042-0000$02.00
   PubMed Web of Science ®Google Scholar
• Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-41; PMID:6176669; http://dx.doi.org/10.1084/jem.155.6.1823
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-84; discussion 484-5; PMID:2679456; http://dx.doi.org/10.1097/00000658-198910000-00008
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
   PubMed Web of Science ®Google Scholar
• Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184:452-65; PMID:19949105; http://dx.doi.org/10.4049/jimmunol.0901101
   PubMed Web of Science ®Google Scholar
• Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12:2353s-8s; PMID:16609058; http://dx.doi.org/10.1158/1078-0432.CCR-05-2503
   PubMedGoogle Scholar
• Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Lienard D, Enk A, Dummer R et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579-88; PMID:9215828; http://dx.doi.org/10.0732-183X/97/1507-0003$3.00/0
   PubMed Web of Science ®Google Scholar
• Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-52; PMID:11956264; http://dx.doi.org/10.1200/JCO.2002.07.044
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-75; PMID:10071291
   PubMed Web of Science ®Google Scholar
• Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23:6747-55; PMID:16170182; http://dx.doi.org/10.1200/JCO.2005.03.202
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20:1600-7; PMID:11896110; http://dx.doi.org/10.1200/JCO.20.6.1600
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17:571-7; PMID:16469753; http://dx.doi.org/10.1093/annonc/mdl007
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology G. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-54; PMID:19001327; http://dx.doi.org/10.1200/JCO.2008.17.5448
   PubMed Web of Science ®Google Scholar
• Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; CD005413; PMID:17253556; http://dx.doi.org/10.1002/14651858.CD005413.pub2
   PubMedGoogle Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-34; PMID:18048825; http://dx.doi.org/10.1200/JCO.2007.12.0253
   PubMed Web of Science ®Google Scholar
• Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015; 42:896-908; PMID:26615134; http://dx.doi.org/10.1053/j.seminoncol.2015.09.028
   PubMed Web of Science ®Google Scholar
• Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372:1689-99; PMID:25923549; http://dx.doi.org/10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 2015; 16:e447-59; PMID:26370354; http://dx.doi.org/10.1016/S1470-2045(15)00246-6
   PubMed Web of Science ®Google Scholar
• De Vita F, Turitto G, di Grazia M, Frattolillo A, Catalano G. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer. Tumori 1998; 84:33-8; PMID:9619711
   PubMed Web of Science ®Google Scholar
• Chen YM, Yang WK, Whang-Peng J, Tsai WY, Hung YM, Yang DM, Lin WC, Perng RP, Ting CC. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J Immunother 1997; 20:354-64; PMID:9336742; http://dx.doi.org/10.1097/00002371-199709000-00004
   PubMed Web of Science ®Google Scholar
• Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N et al. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes 2013; 6:139; PMID:23566546; http://dx.doi.org/10.1186/1756-0500-6-139
   PubMedGoogle Scholar
• Yamamoto N, Honma M, Suzuki H. Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol Pharmacol 2011; 80:466-75; PMID:21606217; http://dx.doi.org/10.1124/mol.110.070862
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Buti S, Camisa R, Brighenti M, Lazzarelli S, Mazza G, Passalacqua R. Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel) 2014; 6:2035-48; PMID:25271833; http://dx.doi.org/10.3390/cancers6042035
   PubMedGoogle Scholar
• Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P et al. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother 2014; 37:360-5; PMID:25075565; http://dx.doi.org/10.1097/CJI.0000000000000044
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 2000; 6(Suppl 1):S76-80; PMID:10685664
   PubMedGoogle Scholar
• Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-8; PMID:18765555; http://dx.doi.org/10.1158/1078-0432.CCR-08-0116
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364:2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987; 328:267-70; PMID:3496540; http://dx.doi.org/10.1038/328267a0
   PubMed Web of Science ®Google Scholar
• Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci 2015; 106:945-50; PMID:25981182; http://dx.doi.org/10.1111/cas.12695
   PubMed Web of Science ®Google Scholar
• Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014; 41:126-32; PMID:24565586; http://dx.doi.org/10.1053/j.seminoncol.2013.12.014
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-8; PMID:10811122
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; http://dx.doi.org/10.1245/ASO.2005.03.536
   PubMed Web of Science ®Google Scholar
• Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25:208-24; PMID:25582080; http://dx.doi.org/10.1038/cr.2015.3
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood-2005-06-2399
   PubMed Web of Science ®Google Scholar
• Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 2010; 33:425-34; PMID:20386464; http://dx.doi.org/10.1097/CJI.0b013e3181cd870f
   PubMed Web of Science ®Google Scholar
• Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99-110; PMID:24292706; http://dx.doi.org/10.1172/JCI46266
   PubMed Web of Science ®Google Scholar
• Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688-96; PMID:22555974; http://dx.doi.org/10.1182/blood-2011-10-386482
   PubMed Web of Science ®Google Scholar
• Gately MK, Anderson TD, Hayes TJ. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol 1988; 141:189-200; PMID:3259967; http://dx.doi.org/10.0022-l767/88/1411-0189$02.0
   PubMed Web of Science ®Google Scholar
• Peace DJ, Cheever MA. Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 1989; 169:161-73; PMID:2783332; http://dx.doi.org/10.1084/jem.169.1.161
   PubMed Web of Science ®Google Scholar
• Assier E, Jullien V, Lefort J, Moreau JL, Di Santo JP, Vargaftig BB, Lapa e Silva JR, Theze J. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 2004; 172:7661-8; PMID:15187148; http://dx.doi.org/10.4049/jimmunol.172.12.7661
   PubMed Web of Science ®Google Scholar
• Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48:5842-8; PMID:3048650
   PubMed Web of Science ®Google Scholar
• Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007; 13:2115-20; PMID:17404094; http://dx.doi.org/10.1158/1078-0432.CCR-06-2509
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother 2011; 34:419-27; PMID:21577143; http://dx.doi.org/10.1097/CJI.0b013e31821dcb50
   PubMed Web of Science ®Google Scholar
• Rao BM, Girvin AT, Ciardelli T, Lauffenburger DA, Wittrup KD. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng 2003; 16:1081-7; PMID:14983090; http://dx.doi.org/10.1093/protein/gzg111
   PubMedGoogle Scholar
• Rao BM, Driver I, Lauffenburger DA, Wittrup KD. Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol 2004; 66:864-9; PMID:15385640; http://dx.doi.org/10.1124/mol.66.4
   PubMed Web of Science ®Google Scholar
• Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol. 2000; 18:1197-202; PMID:11062441; http://dx.doi.org/10.1038/81199
   PubMed Web of Science ®Google Scholar
• Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C et al. Phase I trial of BAY 50–4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007; 13:3312-9; PMID:17545537; http://dx.doi.org/10.1158/1078-0432.CCR-06-1341
   PubMed Web of Science ®Google Scholar
• Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res 1993; 53:2597-602; PMID:8495422
   PubMed Web of Science ®Google Scholar
• Heaton KM, Grimm EA. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Hum Immunol 1995; 42:274-80; PMID:7759316; http://dx.doi.org/10.1016/0198-8859(94)00106-Z
   PubMed Web of Science ®Google Scholar
• Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 2012; 484:529-33; PMID:22446627; http://dx.doi.org/10.1038/nature10975
   PubMed Web of Science ®Google Scholar
• Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-59; PMID:16424916; http://dx.doi.org/10.1038/nrd1957
   PubMed Web of Science ®Google Scholar
• List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013; 5:29-45; PMID:23990735; http://dx.doi.org/10.2147/CPAA.S49231
   PubMedGoogle Scholar
• Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994; 91:9626-30; PMID:7937818; http://dx.doi.org/10.1073/pnas.91.20.9626
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002; 99:1659-65; PMID:11861281; http://dx.doi.org/10.1182/blood.V99.5.1659
   PubMed Web of Science ®Google Scholar
• Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009; 113:2275-83; PMID:19005180; http://dx.doi.org/10.1182/blood-2008-05-160747
   PubMed Web of Science ®Google Scholar
• `Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 2008; 14:4951-60; PMID:18676770; http://dx.doi.org/10.1158/1078-0432.CCR-08-0157
   PubMed Web of Science ®Google Scholar
• Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006; 12:1750-9; PMID:16551859; http://dx.doi.org/10.1158/1078-0432.CCR-05-2000
   PubMed Web of Science ®Google Scholar
• Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 2004; 27:232-9; PMID:15076141; http://dx.doi.org/10.1097/00002371-200405000-00008
   PubMed Web of Science ®Google Scholar
• Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology 2011; 133:206-20; PMID:21426339; http://dx.doi.org/10.1111/j.1365-2567.2011.03428.x
   PubMed Web of Science ®Google Scholar
• Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009; 131:298-307; PMID:19211307; http://dx.doi.org/10.1016/j.clim.2008.12.008
   PubMed Web of Science ®Google Scholar